Heart failure: a PKGarious balancing act.

The pathologically hypertrophied and failing heart is a battlefield in a war that would make even George Lucas proud. On the one side, you have hemodynamic, neurohormonal, morphologic, and cellular/molecular dark forces urging the ventricle towards decompensation and ultimate demise. On the other, Jedi signaling cascades valiantly try to stave off the impending disaster. Alas, unlike the movies, the dark side often wins, and we need better-equipped counter forces to change this. Current heart failure therapies are fairly defensive; blocking neuro-humoral stimuli and hemodynamic overload. However, adaptive/offensive strategies are advancing, including those aimed at enhancing metabolism, vascular supply, and cell regeneration, and those activating molecular signaling to counter maladaptation. (SELECT FULL TEXT TO CONTINUE)

[1]  F. Hofmann,et al.  Relaxins enhance growth of spontaneous murine breast cancers as well as metastatic colonization of the brain , 2011, Clinical & Experimental Metastasis.

[2]  J. Bronzwaer,et al.  Low Myocardial Protein Kinase G Activity in Heart Failure With Preserved Ejection Fraction , 2012, Circulation.

[3]  Anindita Das,et al.  Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. , 2012, Journal of the American College of Cardiology.

[4]  Sang-Eun Lee,et al.  Long-Term Effects of Sildenafil in a Rat Model of Chronic Mitral Regurgitation: Benefits of Ventricular Remodeling and Exercise Capacity , 2012, Circulation.

[5]  D. Kass,et al.  Pressure-Overload–Induced Subcellular Relocalization/Oxidation of Soluble Guanylyl Cyclase in the Heart Modulates Enzyme Stimulation , 2012, Circulation research.

[6]  B. French,et al.  Differential Expression of PDE5 in Failing and Nonfailing Human Myocardium , 2012, Circulation. Heart failure.

[7]  D. Kass,et al.  Pathological Cardiac Hypertrophy Alters Intracellular Targeting of PDE5 from Nitric Oxide Synthase-3 to Natriuretic Peptide Signaling , 2012 .

[8]  W. Linke,et al.  Sildenafil and B-Type Natriuretic Peptide Acutely Phosphorylate Titin and Improve Diastolic Distensibility In Vivo , 2011, Circulation.

[9]  W. Paulus,et al.  Diabetes Mellitus Worsens Diastolic Left Ventricular Dysfunction in Aortic Stenosis Through Altered Myocardial Structure and Cardiomyocyte Stiffness , 2011, Circulation.

[10]  D. Kass,et al.  Phosphodiesterases and cardiac cGMP: evolving roles and controversies. , 2011, Trends in pharmacological sciences.

[11]  Pál Pacher,et al.  Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. , 2011, Circulation.

[12]  J. Corbin,et al.  Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. , 2011, Physiological reviews.

[13]  C. Nediani,et al.  Nitric oxide/reactive oxygen species generation and nitroso/redox imbalance in heart failure: from molecular mechanisms to therapeutic implications. , 2011, Antioxidants & redox signaling.

[14]  R. Arena,et al.  PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study , 2011, Circulation. Heart failure.

[15]  R. Arena,et al.  Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study , 2009, Circulation.

[16]  Dong I. Lee,et al.  Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. , 2010, Journal of the American College of Cardiology.

[17]  Anindita Das,et al.  Long-Acting Phosphodiesterase-5 Inhibitor Tadalafil Attenuates Doxorubicin-Induced Cardiomyopathy without Interfering with Chemotherapeutic Effect , 2010, Journal of Pharmacology and Experimental Therapeutics.

[18]  F. Hofmann,et al.  Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes , 2010, Proceedings of the National Academy of Sciences.

[19]  K. Sipido,et al.  Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice , 2009, Circulation.

[20]  Wolfgang A Linke,et al.  Myocardial Structure and Function Differ in Systolic and Diastolic Heart Failure , 2006, Circulation.

[21]  D. Kass,et al.  Sildenafil Inhibits β-Adrenergic–Stimulated Cardiac Contractility in Humans , 2005 .

[22]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[23]  D. Kass,et al.  Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. , 2005, Circulation.